Cart
sales@molnova.com
CDK8-IN-12
CAS No. 2613307-67-6
CDK8-IN-12( —— )
Catalog No. M36414 CAS No. 2613307-67-6
CDK8-IN-12 is a selective, potent and orally active inhibitor of CDK8 (Ki: 14 nM) and is an anti-cancer agent.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 111 | Get Quote |
|
| 5MG | 163 | Get Quote |
|
| 10MG | 242 | Get Quote |
|
| 25MG | 403 | Get Quote |
|
| 50MG | 586 | Get Quote |
|
| 100MG | 803 | Get Quote |
|
| 200MG | 1098 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameCDK8-IN-12
-
NoteResearch use only, not for human use.
-
Brief DescriptionCDK8-IN-12 is a selective, potent and orally active inhibitor of CDK8 (Ki: 14 nM) and is an anti-cancer agent.
-
DescriptionCDK8-IN-12 is an orally active, potent CDK8 inhibitor with a Ki of 14 nM. CDK8-IN-12 has off-target kinase inhibition on GSK-3α, GSK-3β, PCK-θ with Kis of 13 nM, 4 nM, 109 nM, respectively. CDK8-IN-12 shows potent anti-proliferative effects selectively on MV4-11 cell. CDK8-IN-12 is an anti-cancer agent.
-
In VitroWestern Blot Analysis Cell Line:MV4-11 cells Concentration:0.36, 0.72 μM Incubation Time:2 hours Result:Significantly reduced the phosphorylation of serine 727 on STAT1 at concentrations of their respective 1× GI50 values, but barely affected the level of total STAT1.
-
In Vivo——
-
Synonyms——
-
PathwayPI3K/Akt/mTOR signaling
-
TargetGSK-3
-
RecptorGSK-3 | CDK
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2613307-67-6
-
Formula Weight381.86
-
Molecular FormulaC21H20ClN3O2
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESO=C1C2(CCN(CC2)C=3C(=CN=CC3Cl)C4=CC=5C(O4)=CC=CC5)CCN1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
9-ING-41
9-ING-41 is a glycogen synthase kinase-3 inhibitor.9-ING-41 (2, 4 μM; 48 hours) decreases neuroblastoma cell viability induces apoptosis[2]. 9-ING-41 (0.1-1 μM) inhibits GSK-3 leading to a decreased expression of the NF-κB target XIAP and significant apoptosis in neuroblastoma cells as shown by PARP cleavage, an apoptosis marker[1]. 9-ING-41 (0.5, 1.0, 1.5, 2.0 μM) inhibits the proliferation rate of all TCL and MCL lines with concentrations as low as 1.0 mM.
-
MMBO
MMBO is a potent, highly selective, brain penetrant, orally active inhibitor of GSK-3 with IC50 of 37 and 53 nM for GSK-3α and GSK-3β, respectively.
-
TDZD-8
A potent, selective, non-ATP competitive GSK-3β inhibitor with IC50 of 2 uM; displays no activity against PKA, CK-2, PKC, and CDK1 (IC50>100 uM).
